32 related articles for article (PubMed ID: 38590673)
1. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of Anti-SARS-CoV-2 IgG and IgM Antibodies among Government Employees in Iran.
Mohammad Hossein ZJ; Mehran D
Arch Razi Inst; 2023 Oct; 78(5):1413-1420. PubMed ID: 38590673
[TBL] [Abstract][Full Text] [Related]
3. Antibody tests for identification of current and past infection with SARS-CoV-2.
Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
[TBL] [Abstract][Full Text] [Related]
4. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo.
Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F
Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565
[TBL] [Abstract][Full Text] [Related]
5. Antibody tests for identification of current and past infection with SARS-CoV-2.
Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
7. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
8. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis.
Byambasuren O; Cardona M; Bell K; Clark J; McLaws ML; Glasziou P
J Assoc Med Microbiol Infect Dis Can; 2020 Dec; 5(4):223-234. PubMed ID: 36340059
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Asymptomatic SARS-CoV-2 Infection.
Oran DP; Topol EJ
Ann Intern Med; 2021 Feb; 174(2):286-287. PubMed ID: 33587872
[No Abstract] [Full Text] [Related]
10. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis.
Yanes-Lane M; Winters N; Fregonese F; Bastos M; Perlman-Arrow S; Campbell JR; Menzies D
PLoS One; 2020; 15(11):e0241536. PubMed ID: 33141862
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.
Rudberg AS; Havervall S; Månberg A; Jernbom Falk A; Aguilera K; Ng H; Gabrielsson L; Salomonsson AC; Hanke L; Murrell B; McInerney G; Olofsson J; Andersson E; Hellström C; Bayati S; Bergström S; Pin E; Sjöberg R; Tegel H; Hedhammar M; Phillipson M; Nilsson P; Hober S; Thålin C
Nat Commun; 2020 Oct; 11(1):5064. PubMed ID: 33033249
[TBL] [Abstract][Full Text] [Related]
12. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.
Buitrago-Garcia D; Egli-Gany D; Counotte MJ; Hossmann S; Imeri H; Ipekci AM; Salanti G; Low N
PLoS Med; 2020 Sep; 17(9):e1003346. PubMed ID: 32960881
[TBL] [Abstract][Full Text] [Related]
13. Epidemiologic surveillance for controlling Covid-19 pandemic: types, challenges and implications.
Ibrahim NK
J Infect Public Health; 2020 Nov; 13(11):1630-1638. PubMed ID: 32855090
[TBL] [Abstract][Full Text] [Related]
14. Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis.
Dawood FS; Ricks P; Njie GJ; Daugherty M; Davis W; Fuller JA; Winstead A; McCarron M; Scott LC; Chen D; Blain AE; Moolenaar R; Li C; Popoola A; Jones C; Anantharam P; Olson N; Marston BJ; Bennett SD
Lancet Infect Dis; 2020 Nov; 20(11):1255-1262. PubMed ID: 32738203
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
